Skip to main content

Table 4 Number (%) of patients with serious adverse events (that affected ≥ 2 patients)

From: A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

 

Number (%) of patients*

 

Ganetespib

Ganetespib

Ganetespib

All

7-114 mg/m2

150-216 mg/m2

259 mg/m2

patients

n = 25 (%)

n = 22 (%)

n = 6 (%)

n = 53 (%)

Any event

6 (24)

6 (27.3)

3 (50)

15 (28.3)

Abdominal pain

0

1 (4.5)

1 (16.7)

2 (3.8)

Asthenia

0

1 (4.5)

1 (16.7)

2 (3.8)

Dehydration

0

1 (4.5)

1 (16.7)

2 (3.8)

Pneumonia

0

1 (4.5)

1 (16.7)

2 (3.8)

  1. *A patient may have had more than one event.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us